Aurinia Pharmaceuticals

Aurinia Pharmaceuticals

AUPH· Manufacturing· Fiscal year ends in December

No proxy on file names the CEO of Aurinia Pharmaceuticals.

Executives5

See all
  1. 1Peter GreenleafFY2025
  2. 2Matthew DonleyFY2025
  3. 3Stephen RobertsonFY2025
  4. 4Joe MillerFY2025
  5. 5Greg KeenanFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Aurinia Pharmaceuticals paid its 5 named executives $14.1M in total in FY2025 (Dec).

Name
Peter GreenleafFormer Chief Executive Officer
Matthew DonleyFormer Chief Operating Officer
Stephen RobertsonChief Legal Officer, Corporate Secretary and Chief Compliance Officer
Joe MillerFormer Chief Financial Officer
Greg KeenanFormer Chief Medical Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Aurinia Pharmaceuticals names 20 peer companies for pay. Among Aurinia Pharmaceuticals and these peers, CEO pay was 7th highest of 10 and total shareholder return was 7th highest of 10.

7th highest of 10in Aurinia Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$1.7M$9.7M

7th highest of 10in Aurinia Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$75$364

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Jeffrey A. BaileyDirector · 2 yr on the boardIndependentAudit, Compensation, Governance & Nomination (Chair)—Paid as an executive
  • Kathy GoetzDirector · 0 yr on the boardIndependentCompensation, Governance & Nomination—Paid as an executive
  • Tina S. NovaDirector · 0 yr on the boardIndependentAudit, Governance & Nomination—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Aurinia Pharmaceuticals Former Chief Operating Officer pay fell 11% to $2.2M. The stock rose 78% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Aurinia Pharmaceuticals Former Chief Operating Officer pay fell 45% to $2.5M. The stock did not change in FY2024 (Dec).
    DEF 14A
  3. Pay
    Aurinia Pharmaceuticals Former Chief Medical Officer pay rose 34% to $1.8M. The stock rose 78% in FY2025 (Dec).
    DEF 14A
  4. Board
    Tina S. Nova joined the board of Aurinia Pharmaceuticals. Tina S. Nova sits on no other public board.
    3
  5. Board
    Kathy Goetz joined the board of Aurinia Pharmaceuticals. Kathy Goetz now sits on 2 public boards.
    3
  6. Pay
    Aurinia Pharmaceuticals General counsel pay fell 38% to $2.2M. The stock did not change in FY2024 (Dec).
    DEF 14A
  7. Pay
    Aurinia Pharmaceuticals Former Chief Commercial Officer pay fell 13% to $2.7M. The stock did not change in FY2024 (Dec).
    DEF 14A
  8. Pay
    Aurinia Pharmaceuticals Former Chief Commercial Officer pay rose 11% to $3.1M. The stock rose 108% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Aurinia Pharmaceuticals Former CEO pay fell 39% to $6.4M. The stock did not change in FY2024 (Dec).
    DEF 14A
  10. Pay
    Aurinia Pharmaceuticals COO pay fell 45% to $2.5M. The stock did not change in FY2024 (Dec).
    DEF 14A
  11. Pay
    Aurinia Pharmaceuticals Former CFO pay fell 42% to $2.3M. The stock did not change in FY2024 (Dec).
    DEF 14A
  12. Pay
    Aurinia Pharmaceuticals Former Chief Medical Officer pay fell 13% to $1.3M. The stock did not change in FY2024 (Dec).
    DEF 14A
  13. Pay
    Aurinia Pharmaceuticals EVP, Research and Development pay rose 15% to $3.4M. The stock rose 108% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Aurinia Pharmaceuticals General counsel pay rose 11% to $3.6M. The stock rose 108% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Aurinia Pharmaceuticals General counsel pay rose 348% to $3.2M. The stock fell 81% in FY2022 (Dec).
    DEF 14A
  16. Pay
    Aurinia Pharmaceuticals Former CEO pay rose 20% to $10.6M. The stock rose 108% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Aurinia Pharmaceuticals Former CEO pay rose 612% to $8.8M. The stock fell 81% in FY2022 (Dec).
    DEF 14A
  18. Pay
    Aurinia Pharmaceuticals COO pay rose 38% to $4.6M. The stock rose 108% in FY2023 (Dec).
    DEF 14A
  19. Pay
    Aurinia Pharmaceuticals COO pay rose 353% to $3.3M. The stock fell 81% in FY2022 (Dec).
    DEF 14A
  20. Pay
    Aurinia Pharmaceuticals Former CFO pay rose 21% to $4.0M. The stock rose 108% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 21, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 17, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AMay 3, 2024FY2023
Annual report10-KFeb 15, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data